The EESC welcomes the NRRPs as an unprecedented opportunity to drive change and trigger investments in sustainable growth and creation of quality jobs. It urges the Commission to put in place measures that guarantee structured involvement of the social partners, CSO and youth organisations in the implementation and monitoring of the NRRPs. It calls on the Member States to ensure quality and inclusive guidance and counselling for all young people in order to provide them with more information on their further education and, subsequently, on career possibilities in the context of the green and digital transition of the labour market. Close attention should be paid to the issue of mental health and psycho-social disorders, especially among young people, by reducing the stigma around mental health issues through prevention and awareness-raising work.
zpráva: EU strategy on combating antisemitism and fostering Jewish life
The Commission intends to renew its strategic partnership with the outermost regions, adapting it to the EU priorities on green and digital transition for a stronger recovery after the coronavirus pandemic. The new Communication is expected to be published in April 2022. In this context, the forthcoming French EU Presidency, aims to conclude together with the other EU Member States this new strategic approach to the outermost regions for a green, digital and fair recovery.
stanovisko EHSV: Amendment to the Capital Requirements Regulation in the area of resolution ("daisy chain" proposal)
The EESC strongly supports the goal of redirecting investments in such a way that they contribute to the EU's transition to a sustainable economy but calls for the social partners and civil society to be brought better on board in the design and implementation of sustainable finance. The EU green bond standard has the potential to yield significant economic benefits for both issuers and investors alike and help the green transition.
The Commission proposal amends Regulation (EU) 2017/746 as regards transitional provisions for certain in vitro diagnostic medical devices and deferred application of requirements for in-house devices.